Context Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Context Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Context Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$17.5M, a 197% decline year-over-year.
  • Context Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$30.2M, a 45.3% decline year-over-year.
  • Context Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$24M, a 61.5% decline from 2022.
  • Context Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$14.8M, a 41.9% decline from 2021.
  • Context Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$10.5M, a 257% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$30.2M -$17.5M -$11.6M -197% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$18.6M -$2.25M +$2.76M +55% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$21.3M -$3.67M +$2.64M +41.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$24M -$6.77M -$3.21M -90.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$20.8M -$5.87M -$2.02M -52.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$18.7M -$5.01M -$1.02M -25.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$17.7M -$6.31M -$2.87M -83.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$14.8M -$3.56M -$465K -15% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$14.4M -$3.85M -$2.41M -167% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$12M -$3.99M +$1.04M +20.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$13M -$3.44M -$2.55M -285% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$10.5M -$3.09M -$2.31M -294% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$8.15M -$1.44M -$567K -64.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$7.58M -$5.03M -$12.5M -167% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 $4.93M -$892K -$1.72M -208% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 $6.64M -$785K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 -$876K Jul 1, 2020 Sep 30, 2020 10-Q 2021-12-02
Q2 2020 $7.48M Apr 1, 2020 Jun 30, 2020 10-Q 2021-12-02
Q1 2020 $826K Jan 1, 2020 Mar 31, 2020 10-Q 2021-12-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.